Immunoassay

Cardiac biomarker turnaround time targets in Asia Pacific (2020 data update)

Cardiac_Marker_test_image

A large majority of clinical labs in the Asia Pacific region maintain turnaround time (TAT) targets for cardiac biomarkers, but some countries and laboratory market segments have more ambitious targets than others, according to the latest results from the Asia Pacific Laboratory Benchmarking Survey, an annual survey by Roche Diagnostics that measures the operational effectiveness of […]

Cardiac biomarker turnaround time targets in Asia Pacific (2020 data update) Read More »

HIV testing in the era of PrEP: Practical consideration and challenges in practice

HIV testing in the era of PrEP: Practical consideration and challenges in practice

Conventional HIV testing algorithms may be delayed or compromised in identifying HIV acquisition in the context of antiretroviral agent-based pre-exposure prophylaxis (PrEP). Data are available in delays of progression through the Feibig stages with the use of TDF/FTC PrEP, as well as lower viral load set points. Case reports of complete suppression of nucleic acid detection with PrEP use further

HIV testing in the era of PrEP: Practical consideration and challenges in practice Read More »

Hepatitis C: the patient journey from screening to diagnosis and treatment

Hepatitis C: the patient journey from screening to diagnosis and treatment

An estimated 71 million people around the world are chronically infected with hepatitis C virus (HCV). Marginalised populations, and particularly people who inject drugs, have low testing and treatment rates for HCV. Several models of care and service delivery interventions have the potential to improve outcomes, but much of the relevant research was carried out when interferon-based treatment

Hepatitis C: the patient journey from screening to diagnosis and treatment Read More »

Scroll to Top